Diabetes mellitus type I (DMT1 I is a chronic disease caused by the autoimmune destruction of the insulin-producing beta cells in the pancreas, resulting in an absolute inability to produce the hormone insulin which is necessary for the regulation of blood glucose levels. The autoimmune destruction is postulated to result from an interaction between genetic and environmental factors, with the latter triggering the onset of the disease in genetically susceptible individuals. Various theories explaining the pathogenesis have been proposed in which environmental agents may serve as modifiers of pathogenesis rather than as triggers. These environmental risk determinants may be classified into three groups: viral infections, early postnatal diet, and toxins. Other non-genetic disease modifying factors include vaccine administration, psychological stressors, and climatic influences. The incidence of DMT1 is rapidly increasing in many parts of the developed world, and is showing a trend toward earlier age of onset. The incidence of DMT1 is highly variable among different ethnic populations, occurring most frequently in persons of north European descent, diminishing in southern direction, the 'North-South gradient', with the notable exception of Sardinia. The incidence of DMT1 is projected to be approximately 40 percent higher in 2010 than it was in 1997. The prevalence in The Netherlands is 0.3 percent. Diabetes mellitus type I is characterized by hyperglycemia with the eventual development of micro- and macrovascular complications which define the degree of morbidity in these patients.

, ,
De uitgave van dit proefschrift kwam mede tot stand door financiele bijdragen van de Stichting Medisch Research Fonds Zwolle, Aventis Pharma BV, Bristol-Meyers Squibb BV, Eli Lilly Nederland, GlaxoSmithKiine BV, Novo Nordisk Farma BV en Pfizer BV
M. Berg (Marc) , B. Meyboom de Jong
Erasmus University Rotterdam
hdl.handle.net/1765/32032
Erasmus School of Health Policy & Management (ESHPM)

Hart, B. (2004, June 18). Health Related Quality of Life in Patients with Diabetes Mellitys Type I. Retrieved from http://hdl.handle.net/1765/32032